Eterna Therapeutics (ERNA) Income Statement
316 Followers
Eterna Therapeutics Income Statement
Last quarter (Q2 2026), Eterna Therapeutics's total revenue was $0.00. In Q2, Eterna Therapeutics's net income was $-4.01M. See Eterna Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| $ 0.00 | $ 582.00K | $ 68.00K | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ 486.00K | $ -168.00K | $ 0.00 | $ 0.00 | |
| $ 9.32M | $ 16.16M | $ 20.97M | $ 33.22M | $ 113.73M | |
| Depreciation and Amortization | $ 263.00K | $ 1.64M | $ 1.12M | $ 497.00K | $ 459.00K |
| $ -13.84M | $ -36.12M | $ -19.93M | $ -24.01M | $ -121.95M | |
| $ -9.32M | $ -15.67M | $ -21.14M | $ -33.22M | $ -113.73M | |
| $ -4.81M | $ -28.84M | $ -536.00K | $ 8.68M | $ -8.75M | |
| $ -14.13M | $ -44.51M | $ -21.67M | $ -24.53M | $ -122.48M | |
| $ -14.08M | $ -44.54M | $ -21.67M | $ -24.58M | $ -122.55M | |
| Per Share Metrics | |||||
| Basic EPS | $ -56.00 | $ -39.25 | $ -102.00 | $ -201.50 | $ -1415.25 |
| Diluted EPS | $ -56.00 | $ -39.25 | $ -102.00 | $ -201.50 | $ -1415.25 |
| Weighted Average Shares Outstanding | 252.28K | 1.14M | 212.56K | 122.04K | 86.60K |
| Weighted Average Shares Outstanding (Diluted) | 252.28K | 1.14M | 212.56K | 122.04K | 86.60K |
Currency in USD
